Acquisition - March 6, 2014
Bayer completes voluntary takeover offer for Algeta
The Bayer Group has completed the voluntary takeover offer for Norwegian pharmaceutical company Algeta. According to a statement from Bayer, the payment of the offer price has been made to Algeta’s shareholders who accepted the takeover offer and, at the same time, the 43,131,641 tendered shares have been transferred to Bayer. As a result, Bayer […]
Acquisition - February 18, 2014
Actavis to Buy Forest Labs
Actavis PLC plans to buy Forest Laboratories Inc. for about $25 billion. “With this strategic combination, we create an innovative new model in specialty pharmaceuticals leadership, with size and scale, a balanced offering of strong brands and generics, a focus on strategic, lower-risk drug development, and – most important – the ability to drive sustainable […]
Acquisition - February 3, 2014
AstraZeneca completes acquisition of BMS diabetes share
AstraZeneca has completed the acquisition of the entirety of Bristol-Myers Squibb’s interest in the companies’ diabetes alliance. In December last year, the news about the acquisition were announced and on February 1 2014 the deal was completed. According to the agreement, AstraZeneca gets ownership of the intellectual property and global rights for the development, manufacture and […]
Acquisition - December 20, 2013
Bayer buys Algeta
Bayer plans to acquire Norwegian pharmaceutical company Algeta. The Bayer Group plans to further strengthen its oncology portfolio with the acquisition of Norwegian pharmaceutical company Algeta ASA, Oslo, according to a press release. Bayer has already collaborated with Algeta to develop and commercialize the cancer drug Xofigo. The planned acquisition would give Bayer full control […]
Acquisition - December 10, 2013
Moberg Pharma acquires OTC brands in the US from Bayer HealthCare
Moberg Pharma has signed a deal to acquire three well established Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC. Total annual sales for the brands are approximately 20 MSEK (ca 3 m$). The purchase price is 32 MSEK (4.8 m$) and is financed by available cash resources. The acquired portfolio includes Domeboro®, a topical […]
Acquisition - October 23, 2013
Alligator acquires Atlas Therapeutics
Alligator Bioscience will gain strong connections to both the world leading research performed by professor Mathias Uhlén at the SciLifeLab and the HPA project in Stockholm/Uppsala as well as the CREATE Health Translational Cancer Center at the University of Lund. Alligator Bioscience will remain based in Medicon Village in Lund and with Sibylle Lenz as […]
